Status:
COMPLETED
ATRi Transition Rollover Study
Lead Sponsor:
Merck KGaA, Darmstadt, Germany
Conditions:
Advanced Stage Solid Tumors
Eligibility:
All Genders
Phase:
PHASE1
Brief Summary
The main purpose of the study was to monitor the safety of participant receiving long-term treatment of Berzosertib as monotherapy.
Eligibility Criteria
Inclusion
- Participants ongoing treatment in Vertex study VX13-970-002.
- Participant must be able to understand and provide written informed consent.
- Participant must be willing and able to comply with the scheduled visits, treatment plan, lifestyle, laboratory tests, contraceptive guidelines, and other study procedures.
Exclusion
- Participants experiencing disease progression or unacceptable toxicity at the time of transition into the this study.
Key Trial Info
Start Date :
January 10 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 26 2024
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT03309150
Start Date
January 10 2018
End Date
January 26 2024
Last Update
November 29 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal Marsden NHS Foundation Trust
Sutton, United Kingdom